Neuropsychiatric biomarker discovery: go big or go home

Alicia Ljungdahl; Stephan J Sanders

doi:10.1016/j.molmed.2023.09.002

Neuropsychiatric biomarker discovery: go big or go home

Trends Mol Med. 2023 Nov;29(11):878-879. doi: 10.1016/j.molmed.2023.09.002. Epub 2023 Sep 14.

Authors

Alicia Ljungdahl¹, Stephan J Sanders²

Affiliations

¹ Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK; Department of Psychiatry and Behavioral Sciences, UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA 94158, USA.
² Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK; Department of Psychiatry and Behavioral Sciences, UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA 94158, USA. Electronic address: stephan.sanders@paediatrics.ox.ac.uk.

Abstract

Technological advances have enabled high-throughput omics assays, such as parallelized screening of lipids across plasma samples. Pioneering a new paradigm for neuropsychiatric biomarker discovery, Yap et al. describe a large-scale systematic analysis of comprehensive phenotypic, genotypic, environmental, and lipidomic data to unravel the intricate interplay between these and autism-associated traits.

Keywords: biomarkers; lipidomics; neuropsychiatry; omics.

MeSH terms

Biomarkers / analysis
Biomedical Research*
High-Throughput Screening Assays
Humans

Substances

Biomarkers

Abstract

MeSH terms

Substances

Grants and funding